Compare Eli Lilly And Co (LLY) vs Invesco S&P 500 High Div Low Volatility ETF (SPHD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Invesco S&P 500 High Div Low Volatility ETF — how do they compare? Eli Lilly And Co trades at $1,178.99 (market cap $1.04T), while Invesco S&P 500 High Div Low Volatility ETF trades at $48.79 (market cap $3.14B). The key difference: Eli Lilly And Co is far larger — about 331.2× Invesco S&P 500 High Div Low Volatility ETF's market cap, and Eli Lilly And Co pays a 0.59% dividend while Invesco S&P 500 High Div Low Volatility ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Invesco S&P 500 High Div Low Volatility ETF for 125 Days on average.
| LLY | SPHD | |
|---|---|---|
Market Cap | $1.04T | $3.14B |
Volume | 3,064,878 | 1,461,349 |
Sector | Health | — |
52-Week High | $1.28K | $53.55 |
52-Week Low | $799.57 | $46.96 |
Typical Hold Time | 93 Days | 125 Days |
Enterprise Value | $1.09T | — |
Dividend Yield | 0.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,176.69, down 1.01% on the day, amid a bullish technical outlook and strong fundamental performance. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 consensus. Revenue surged to $65.18B in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing growth prospects.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include elevated valuation multiples and competitive pressures in the pharmaceutical sector. With a consensus price target of $1,350, upside potential exists, but investors should weigh execution risks against the company's innovation pipeline.
SPHD trades at $48.71, up 1.08% with a bearish technical outlook showing 17 sell signals versus 4 buys. The ETF focuses on high dividend yield and low volatility S&P 500 stocks, offering monthly income distribution. Recent dividend payments of $0.20-$0.21 demonstrate consistent income generation, though technical indicators suggest near-term pressure.
While SPHD provides attractive monthly dividends for income-focused investors, the bearish technical signals and concerns about total return performance compared to peers like SCHD present near-term headwinds. The fund's low volatility mandate may provide defensive positioning during market uncertainty, but investors should weigh income benefits against potential capital appreciation limitations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Invesco S&P 500 High Div Low Volatility ETF
The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. Strictly in accordance with its guidelines and mandated procedures, S&P Dow Jones Indices LLC (the “index Provider”) compiles, maintains and calculates the underlying index, which is designed to measure the performance of 50 least volatile high yielding constituents of the S&P 500 ® Index in the past year.
Read more on SPHD →
